Actively Recruiting
"Perfect Heartio" Drink and Cardiovascular Health
Led by The Perfect Series Sdn Bhd · Updated on 2025-07-08
55
Participants Needed
1
Research Sites
39 weeks
Total Duration
On this page
Sponsors
T
The Perfect Series Sdn Bhd
Lead Sponsor
U
UCSI University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Noncommunicable diseases (NCDs) such as type 2 diabetes (T2D) and cardiovascular disease (CVD) account for more deaths globally than any other condition. In 2018, the WHO reported that NCDs accounted for 71% of global deaths. They also showed that low- and middle-income countries are disproportionately affected by NCDs, accounting for 85% of NCD-related deaths among individuals aged 30-69 y. Among NCDs, CVD is the leading and fourth-leading causes of death, accounting for 19.5 million deaths worldwide in 2018. Furthermore, despite increasing global awareness, the prevalence of these conditions continues to increase at alarming rates. Deaths from CVD are expected to reach 23.6 million annually by 2030 from 17.6 million deaths in 2016. The underlying aetiology of these conditions is complex, as they can be influenced by several environmental, genetic, and behavioural factors. However, diet and nutrition play a particularly important role in these conditions, especially in the context of the double burden of malnutrition facing many low- and middle-income countries.
CONDITIONS
Official Title
"Perfect Heartio" Drink and Cardiovascular Health
Who Can Participate
Eligibility Criteria
You may qualify if you...
- General healthy subjects during enrolment
- Age 18 and above
- Willing to comply with interventional plan and comes to do follow up
- Willing to gives consent
You will not qualify if you...
- Use nonsteroidal anti-inflammatory drugs (NSAIDs) more than once a week during enrolment
- Use of anticoagulants or corticosteroids
- Use of individual supplements of vitamin A, E, or beta carotene more than once a week during enrolment
- Renal failure or dialysis, cirrhosis, other serious conditions that precluded participation
- No previous history of cancer (except nonmelanoma skin cancer)
- Pregnant or lactating woman
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UCSI University
Cheras, Kuala Lumpur, Malaysia, 56000
Actively Recruiting
Research Team
C
Chung Keat Tan, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
PREVENTION
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here